PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-3427

  1. 821 Posts.
    lightbulb Created with Sketch. 328
    From an overall yup we know it works this is very encouraging.
    From a whos PPS is it is in my opinion very important as if it’s not Bene then we potentially have a replica that the FDA are initially comfortable with approving in animals so humans are only a matter of time.
    Is this where PARs patents protect us from us to treat BML’s in Knees?

    I seriously think fast track / accelerated approval is on the cards as the evidence is stacking up…

    The Pool
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.